Pharma & Biotech Industry Analysis, from Thought Leaders
Refine Search
Biotechnology
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Pharmaceutical
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Pharmaceutical
An Analysis of M&A activity in the CNS space. 26 July 2024
Pharmaceutical
The biopharmaceutical supply chain plays a pivotal role in ensuring the seamless delivery of therapeutics to patients. However, pharmaceutical supply chains face several challenges, including regulatory complexities, global competition, and the need for innovation. 26 July 2024
Pharmaceutical
Anticipation had been building for many weeks, but when the UK’s general election finally took place on 4 July, the outcome felt entirely inevitable. 9 July 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Pharmaceutical
An analysis of the investment activity of Novartis in recent years. 5 April 2024
Pharmaceutical
An analysis of recent pharma activity in the metabolic diseases field and why obesity is a hot topic amongst investors. 8 March 2024
Pharmaceutical
When James Burt, the chief executive of lifecycle management healthcare company Pharmanovia, looks back at the mood in the pharma industry in 2023, he is happy to say that he is already experiencing a greater sense of optimism in 2024. 27 February 2024
Pharmaceutical
Danish drugmaker Lundbeck has its eye on steady growth over the medium term, a strategy which new chief executive Charl van Zyl believes could be key to the firm’s future success. 12 February 2024
Biotechnology
By Barbara Obstoj-Cardwell. Editor
In full year 2023, the total number of mergers and acquisitions (M&A) in the pharma and biotech sectors was 105, compared with 109 in 2022 and just 92 in 2021, according to tracking by The Pharma Letter (TPL). 4 January 2024
Biosimilars
In the two decades since biosimilars emerged on the world stage, their evolution has brought acceptance of the critical role they can play in making life-changing therapies more affordable. 22 December 2023
Pharmaceutical
A feature analyzing recent pharma activity in the hepatology field and why NASH remains unchartered territory. 20 December 2023
Pharmaceutical
The most recent new treatment for Alzheimer’s disease was approved by European regulators in May 2002, with the US Food and Drug Administration following suit the next year. 26 July 2017
Pharmaceutical
The pharmaceutical industry is a prime target for hackers. In 2015, a survey by Crown Records Management revealed that nearly two thirds of pharma firms had experienced breaches in data, and that one fourth of these same companies had been victims of hacking. 18 July 2017
Pharmaceutical
Twenty-seven years ago last January, a letter in the New England Journal of Medicine concluded that: “despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.” 12 July 2017
Pharmaceutical
Dr Nicola Davies looks at how real world evidence carries ever greater importance in an industry where often regulatory approval alone is no longer enough. 4 July 2017
Pharmaceutical
Anyone unfamiliar with pharma might be puzzled by how often the word ‘innovation’ comes up in dialogue, campaigning and marketing messages. 24 June 2017
Biosimilars
Under a coruscating Spanish sun, the 17th Annual European Congress of Rheumatology, EULAR, has at last drawn to a close in Madrid. 20 June 2017
Pharmaceutical
Dr Nicola Davies explores an issue which will determine how pharma companies retain their prominence in the industry. 12 June 2017
Biotechnology
With so much of the exciting data at ASCO 2017 again surrounding cancer immunotherapies, The Pharma Letter finds confidence that more will follow in the footsteps of Merck & Co's Keytruda (pembrolizumab). 8 June 2017
Biosimilars
With data on so many innovative but expensive new oncology treatments being presented at ASCO 2017, it is a crucial period for biosimilars of three of the world's biggest-selling cancer drugs to deliver their promised savings, and this feature looks at the progress of these copycat biologics in reaching markets and patients. 1 June 2017
Pharmaceutical
In the run up to the annual meeting of the American Society of Clinical Oncology, we present the first of three analyses focusing on the state of cancer research and care. This week, our correspondent Simon Wentworth reviews progress in the much-anticipated field of precision oncology. 23 May 2017
Biotechnology
With a global society of researchers, regulators and clinicians celebrating its 25th anniversary, 2017 is a good time to consider how cellular therapies have progressed in this period, where they are now, and the obstacles preventing their advance in the next quarter-century. 16 May 2017
Pharmaceutical
While pharma companies pile into areas such as oncology and central nervous system disorders in the hope that they can offer the next lifesaving treatment, the fact that there are currently just six global players in the vaccines space indicates that it is an enormously challenging area despite the enormous benefits of immunizations for healthcare systems. 9 May 2017
Pharmaceutical
In the midst of a comprehensive cost cutting program rumored to include thousands of job losses, Teva chief financial officer Eyal Desheh is about to quit, Israeli press reports. 3 May 2017
Pharmaceutical
While drugmakers tend to gravitate towards the mature markets, they’re also naturally keen to identify investment opportunities elsewhere. After all, sales outside of the the EU, USA and Japan account for about 20% of the global pharmaceuticals market. 24 April 2017
Biotechnology
Biotherapeutics is the fastest-growing sector in the pharmaceutical industry, with total revenues reaching up to $163 billion. 17 April 2017
Pharmaceutical
With the last set of 2016 financial results of a big-name pharma presented last week, it is possible – when they are viewed in a wider context – to gain some insight into the direction of the industry in analyzing the performance, outlook and pipeline of many of the major players. 10 April 2017
Pharmaceutical
Diabetes has shifted from being a chronic condition that affects a few, to being a global epidemic that is responsible for considerable morbidity and mortality worldwide. 3 April 2017
Pharmaceutical
The application of cost-effectiveness criteria is a hallmark of the UK’s approach to health technology assessment, differentiating it from many other European countries. It’s an approach which raises ethical considerations around access to medical technology; which drugs we should fund and which diseases, which patients, we should treat. 22 March 2017
Pharmaceutical
Recent figures confirm a continuous rise in rates of overweight and obesity. Since the 1980s, the prevalence of both conditions has more than doubled worldwide. In 2014, more than half of the adult population was tackling weight issues, with 13% living with obesity and 39% being overweight. 20 March 2017
Pharmaceutical
Physicians, pharma or regulators – who has caused the US opioid crisis? And how can they solve it? 13 March 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze